Table 1.

Vaccine efficacies and virus neutralizing antibody titers for current vaccines completing phase 3 trials with pending our actual emergency use authorization.

Vaccine (Type)	Efficacy vs original strains 2 doses	Efficacy vs original strains 1 dose	Virus neutralizing antibodies vs original	Efficacy vs B.1.351 from ZA 2 Doses	Efficacy vs B.1.351 from ZA 1 Dose	Virus neutralizing antibodies vs B.1.351
Pfizer BNT162b2 (mRNA)	95% [1]	52% [12 days after immunization] [1] Israel study 51% infection [3], [4], Alternative analysis 92.6% later analysis after 14 days [7]	Geometric mean titer (GMT), plaque reduction neutralizing titers (PRNT) vs USA–WA1/2020 = 532 [2] GMT PRNT 437 in Phase 1 [5]	Not available (N.A.)	N.A.	GMT PRNT vs USA - B.1.351 = 194 [2]
Moderna (mRNA-1273)	94% [6]	92% 14 days after immunization [7]	GMT PRNT 340-654 range in 100 ug dose [8]	N.A.	N.A.	VSV Pseudovirus neutralization assay 6.4X reduction [9]
J&J (Ad26)	N.A.	72% in US [10]	827-1266 in 2 doses [11]	N.A.	57% in ZA [10]	N.A.
AZOx (ChAdOx1)	Overall 70% [12] 62% in 2 standard doses [12] 90% low dose followed by standard dose [12]	N.A.	GMT 218 [14]	10.4% [13]	N.A.	N.A.
Novavax (Particle)	89.3% [15]	N.A.	GMT 3305–3906 [16]	60% [15]	N.A.	N.A.
Russia Gemalaya (Ad26/Ad5)	92% [18]	N.A.	GMT 45–49 [17]	N.A.	N.A.	N.A.
Chinese Sinovac (WIV)	50% in Brazil [19]	N.A.	GMT 50 (over age of 60) [20]	N.A.	N.A.	N.A.
Chinese Sinopharm (WIV)	79% [21]	N.A.	GMT 218–282 [22]	N.A.	N.A.	N.A.
Chinese CanSinoBio (Ad5)	N.A.	66% in Pakistan, 90% severe disease [23]	GMT 18–19 [24]	N.A.	N.A.	N.A.
Bharat	N.A.	N.A.	GMT 48–66 [25]	N.A.	N.A.	N.A.